(19)
(11) EP 4 816 412 A1

(12)

(43) Date of publication:
07.10.2026 Bulletin 2026/41

(21) Application number: 24898840.4

(22) Date of filing: 28.11.2024
(51) International Patent Classification (IPC): 
C07K 16/32(2006.01)
A61P 35/00(2006.01)
C07K 16/46(2006.01)
A61K 39/395(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/32; A61P 35/00; C07K 2317/31; C07K 2317/35; C07K 2317/622; C07K 2317/55; C07K 2317/73; C07K 2317/92
(86) International application number:
PCT/US2024/057935
(87) International publication number:
WO 2025/117871 (05.06.2025 Gazette 2025/23)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 29.11.2023 US 202363604087 P

(71) Applicant: SystImmune, Inc.
Redmond WA 98052 (US)

(72) Inventors:
  • RENSHAW, Blair
    Renton, Washington 98058 (US)
  • ZHU, Yi
    Redmond, Washington 98052 (US)

(74) Representative: Mathys & Squire 
32 London Bridge Street The Shard
London SE1 9SG
London SE1 9SG (GB)

   


(54) BISPECIFIC TETRAVALENT ANTIBODY TARGETING HER2 AND HER3